Inozyme Pharma (INZY) News Today

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

$4.51

-0.07 (-1.53%)

(As of 04/19/2024 ET)

Source

Source	Headline
	Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update americanbankingnews.com - April 16 at 4:22 AM
	Inozyme Pharma (NASDAQ:INZY) Given Buy Rating at Needham & Company LLC americanbankingnews.com - April 10 at 4:48 AM
	Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $14.00 by Analysts at Bank of America americanbankingnews.com - April 10 at 3:54 AM
	Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA) markets.businessinsider.com - April 9 at 1:51 PM
	Bank of America Lowers Inozyme Pharma (NASDAQ:INZY) Price Target to $14.00 marketbeat.com - April 9 at 1:31 PM
	Needham & Company LLC Reaffirms "Buy" Rating for Inozyme Pharma (NASDAQ:INZY) marketbeat.com - April 9 at 8:24 AM
	Inozyme Pharma (NASDAQ:INZY) Earns Outperform Rating from Wedbush americanbankingnews.com - April 9 at 3:28 AM
	Inozyme Pharma's (INZY) "Outperform" Rating Reaffirmed at Wedbush marketbeat.com - April 8 at 5:25 PM
	Inozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock Up markets.businessinsider.com - April 8 at 7:45 AM
	Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency globenewswire.com - April 8 at 6:30 AM
	Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - April 5 at 6:00 PM
	Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares insidertrades.com - April 4 at 6:52 AM
	Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference globenewswire.com - April 2 at 8:30 AM
	Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 globenewswire.com - March 26 at 8:30 AM
	FY2024 EPS Estimates for Inozyme Pharma, Inc. Lowered by Analyst (NASDAQ:INZY) marketbeat.com - March 15 at 7:22 AM
	Inozyme Pharma, Inc. (NASDAQ:INZY) to Post Q1 2024 Earnings of ($0.35) Per Share, HC Wainwright Forecasts marketbeat.com - March 14 at 6:39 AM
	Buy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701 markets.businessinsider.com - March 13 at 2:02 PM
	Inozyme Pharma: Q4 Earnings Insights benzinga.com - March 12 at 7:45 PM
	Inozyme Pharma: Q4 Earnings Insights benzinga.com - March 12 at 7:45 PM
	Buy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidence markets.businessinsider.com - March 12 at 7:45 PM
	Buy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster Confidence markets.businessinsider.com - March 12 at 7:45 PM
	Inozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market Underappreciation markets.businessinsider.com - March 12 at 7:45 PM
	Inozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by Wedbush marketbeat.com - March 12 at 2:26 PM
	Inozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights finanznachrichten.de - March 12 at 2:03 PM
	Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights globenewswire.com - March 12 at 8:30 AM
	Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Schonfeld Strategic Advisors LLC marketbeat.com - March 10 at 5:38 AM
	Fmr LLC Increases Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) marketbeat.com - March 8 at 4:24 AM
	Adage Capital Partners GP L.L.C. Acquires 1,287,500 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) marketbeat.com - March 7 at 7:44 AM
	Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Rock Springs Capital Management LP marketbeat.com - March 5 at 7:37 PM
	Eventide Asset Management LLC Makes New Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) marketbeat.com - March 1 at 9:32 AM
	Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference globenewswire.com - February 26 at 8:30 AM
	INZY May 2024 5.000 put finance.yahoo.com - February 25 at 10:33 AM
	Inozyme Pharma Stock (NASDAQ:INZY), Short Interest Report benzinga.com - February 24 at 5:50 PM
	Bakker Juliet Tammenoms's Net Worth benzinga.com - February 22 at 7:03 PM
	Inozyme Pharma, Inc. (INZY) finance.yahoo.com - January 30 at 1:57 PM
	Inozyme Pharma Inc Ordinary Shares INZY morningstar.com - January 19 at 11:13 PM
	Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY) finance.yahoo.com - December 21 at 8:33 AM
	TD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY) markets.businessinsider.com - November 9 at 12:02 AM
	Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights finance.yahoo.com - November 7 at 9:59 AM
	Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023 finance.yahoo.com - October 26 at 1:07 PM
	Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade msn.com - October 10 at 1:48 PM
	Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions finance.yahoo.com - October 10 at 8:47 AM
	Denali Advisors LLC Invests $149,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) marketbeat.com - September 29 at 6:43 AM
	Inozyme Pharma (NASDAQ:INZY) Rating Reiterated by Needham & Company LLC marketbeat.com - September 27 at 8:13 AM
	Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders msn.com - September 26 at 7:57 PM
	Promising Trial Results and Financial Stability Bolster Buy Rating for Inozyme Pharma’s Stock (INZY) markets.businessinsider.com - September 26 at 2:56 PM
	Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023 finance.yahoo.com - September 20 at 1:07 PM
	Wedbush Maintains Inozyme Pharma (INZY) Outperform Recommendation msn.com - September 9 at 4:59 PM
	Analyst Expectations for Inozyme Pharma's Future markets.businessinsider.com - September 8 at 5:53 PM
	Wedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY) marketbeat.com - September 8 at 1:58 PM

Get Inozyme Pharma News Delivered to You Automatically

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

INZY Media Mentions By Week

INZY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INZY
News Sentiment
▼
1.90

0.51
▲
Average
Medical
News Sentiment

INZY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INZY Articles
This Week
▼
1

1
▲
INZY Articles
Average Week

Get Inozyme Pharma News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:INZY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inozyme Pharma (INZY) News Today

INZY Media Mentions By Week

INZY Media Sentiment

INZY News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info